- Company
- NSCLC drug Rybrevant can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 15, 2022 05:55am
- Janssen’s new lung cancer drug Rybrevant can now be prescribed at general hospitals in Korea. According to industry sources, the anticancer drug Rybrevant (amivantamab), which is used to treat EGFR exon 20 insertion non-small-cell lung cancer (NSCLC) that is insensitive to currently available EGFR tyrosine kinase inhibitors (TKIs), has
- Company
- JW Pharm sells ₩10 bil with Actemra in 1H 2022
- by Chon, Seung-Hyun Sep 15, 2022 05:55am
- Actemra, JW Pharmaceutical’s rheumatoid arthritis treatment, rose and settled as the company’s flagship product, exceeding KRW 10 billion in sales in 1H this year. The product's increase in sales was fueled by the increase in its prescription as a rheumatoid arthritis treatment and its increased use as a COVID-19 treatment. According to the
- Company
- The NHIS signed a MOU with Viatris to manage chronic dz
- by Eo, Yun-Ho Sep 15, 2022 05:55am
- Viatris is working with the NHIS to improve the chronic disease management environment. The NIHS and Viatris signed a MOU at the headquarters of the Wonju Industrial Complex in Gangwon-do on the 1st to utilize educational materials for patients with chronic medical care. Through this business agreement, the two institutions said they will
- Company
- Complicated patent extension period than foreign countries
- by Kim, Jin-Gu Sep 14, 2022 05:50am
- The current system is advantageous for multinational companies, and many domestic companies welcome reorganization. The system for extending the duration of drug patents is expected to be reorganized. The Korean Intellectual Property Office established a related TF and prepared an improvement plan, and recently inquired about opinions in the
- Company
- Novartis Korea to close down Respiratory BU next month
- by Sep 14, 2022 05:50am
- Novartis Korea is expected to close down its Respiratory Business Unit and dispose of related products from October this year. According to industry sources on the 14th, Novartis Korea’s Respiratory Business Unit will be officially closed down next month as part of the company’s large-scale reorganization in progress at the global level.
- Company
- Tylenol-focused sales for COVID-19-related use dispersed
- by Kim, Jin-Gu Sep 14, 2022 05:50am
- The stock shortage of major over-the-counter drugs used to relieve symptoms of COVID-19, such as general cold medicines and antipyretic analgesics, has been prolonged due to the resurgence of COVID-19. In this prolonged shortage, the demand that had been concentrated on Tylenol is being dispersed to other drugs. Tylenol was the only major hou
- Company
- Novartis' application for voluntary retirement is closed
- by Sep 14, 2022 05:50am
- The application for ERP, which is underway by Novartis Korea, has ended. Attention is focusing on whether the relatively quiet voluntary retirement will be completed without any problems. According to the pharmaceutical industry on the 8th, the application for voluntary retirement, which was conducted by Novartis Korea for about two weeks,
- Company
- Hanmi’s Rolontis receives US FDA marketing approval
- by Kim, Jin-Gu Sep 13, 2022 05:52am
- Hanmi Pharmaceutical’s neutropenia treatment ‘Rolontis (US product name: Rolvedon)' received approval from the US FDA. Hanmi Pharmaceutical and its partner Spectrum Pharmaceuticals announced on the 9th (local time) that it had received written notice of approval allowing for the marketing authorization of Rolontis from the FDA. This is t
- Company
- Unilateral voluntary retirement
- by Sep 8, 2022 05:59am
- The GSK labor union of Korea has taken legal action, insisting on the management's unilateral voluntary retirement. The company is not taking any action, but the inside is "like the calm before the storm" as legal battles are predicted. Novartis Korea, where voluntary retirement is being carried out relatively quietly, is also nervous until t
- Company
- Sales of immuno-cancer drugs exceeded 200 billion won
- by Sep 8, 2022 05:58am
- In the first half of this year, the domestic immune anticancer drug market surpassed 200 billion won. In particular, Opdivo's performance, which showed his endurance, was remarkable. Opdivo sales increased 41% from the previous year, surpassing 50 billion won in half-year sales. According to IQVIA, a pharmaceutical market research firm, th
